Project scope

Key areas of interest:

Malaria

1)  Identification and characterization of novel antimalarial modes of action using both phenotypic and target based approaches - to enable selection and development of safe potential drugs promoting fast clearance of parasites by the host and/or blocking transmission
2)  Understanding mechanisms of antimalarial resistance and the development of assays to anticipate impact in the clinical setting
3)  Antimalarial PK/PD translational models to understand key parameters affording a drug its antimalarial effect
4)  Assess new culture systems for Plasmodium species including P. vivax liver stages

  • To enable screening and identification of anti-hypnozoite drugs
  • To ensure 'pan-active' activity of antimalarials in all Plasmodium species (falciparum, vivax, ovale, malariae & knowlesi)
5)  Translational in vitro and in vivo models to assess transmission blocking potential
6)  Evaluation of combination regimens through development of in vivo, in vitro and ex vivo models

Tuberculosis

1)  Exploitation of novel small molecule screening approaches beyond commonly employed phenotypic strategies (i.e. more relevant to mycobacterial survival in the host)
2)  Access to unexplored chemical space, natural products and other sources of compounds as hits/leads in TB discovery programs.
3)  In vivo technologies and disease models with increased translational value.
4)  Target based approaches on genetically and chemically validated TB and host targets.
5)  Novel approaches to screen and identify additive or synergistic drug combinations.

Kinetoplastids

1)  Novel libraries and assays to identify compounds against Leishmaniasis and Chagas disease.
2)  Animal models that allow the quick evaluation, ranking and establishment of PK/PD relationships of drug leads against Leishmania and Chagas disease.
3)  Target based approaches on genetically and chemically validated anti-Kinetoplastid and host targets.